...
首页> 外文期刊>Journal of Medicinal Chemistry >Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists
【24h】

Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists

机译:发现新型氰基二氢吡啶类化合物作为有效的盐皮质激素受体拮抗剂

获取原文
获取原文并翻译 | 示例

摘要

A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R_6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R_6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.
机译:据报道,一种新的1,4-二氢吡啶5a在C3位上含有一个氰基,在体外具有出色的盐皮质激素受体(MR)拮抗剂,并且没有钙通道阻滞剂(CCB)活性。在本研究中,我们报告了这个氰基酯二氢吡啶类新系列化合物的结构活性关系,该关系导致R_6取代的类似物具有改善的代谢稳定性,同时保持出色的MR拮抗剂活性和对其他核受体的选择性。通过在R_6处引入五元环杂环进行进一步的结构优化,得到的化合物具有出色的MR拮抗剂效能和合适的药代动力学特征。在对Dahl盐敏感的高血压大鼠模型中有前途的工具化合物的体内研究表明,与类固醇MR拮抗剂依普利农相似,血压(BP)降低相似,为非甾体,口服有效的MR拮抗剂提供了概念验证(POC) 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号